NeoGenomics Validates and Launches NeoSITE™ Barrett's Esophagus FISH Test for Surveillance and Diagnosis of High Grade

NeoGenomics Validates and Launches NeoSITE™ Barrett's Esophagus FISH Test for
     Surveillance and Diagnosis of High Grade Dysplasia/Esophageal Cancer

PR Newswire

FT. MYERS, Fla., Dec. 17, 2012

FT. MYERS, Fla., Dec. 17, 2012 /PRNewswire/ --NeoGenomics, Inc. (NASDAQ:
NEO), a leading provider of cancer-focused genetic testing services, announced
today it has validated and launched a laboratory developed Fluorescent in Situ
Hybridization ("FISH") assay for the surveillance of patients with Barrett's
Esophagus ("BE"). The test is highly sensitive for the detection of the
presence of esophageal cancer or high grade dysplasia indicative of
precancerous changes.

Approximately 3 million Americans suffer from Barrett's Esophagus in the
United States, a condition which can be a precursor to esophageal cancer.
Although less than 1% of these patients develop cancer each year, esophageal
carcinoma is frequently not detected until later stages, at which point
therapy options are limited, extremely invasive, and often ineffective.
Therefore, early detection is important and regular surveillance is
recommended. Endoscopic examinations with multiple tissue biopsies to look
for dysplasia and cancer have long been considered the standard surveillance
procedure for BE patients. However, current data suggests that an esophageal
"brushing" may be more effective than a traditional tissue biopsy, because it
allows for the collection of cells from a larger area of the esophagus for
testing, which results in less sampling error. Esophageal brushings are also
generally easier and less costly to obtain than tissue biopsies.

NeoGenomics' NeoSITE™ Barrett's Esophagus FISH test was designed specifically
to be performed on brushing samples and can be used as an objective and easier
means to aid in routine surveillance of BE patients. The Company performed an
extensive trial to validate this new test in which the test showed initial
sensitivity of 86% and specificity of 67% when the Company's proprietary
algorithms were used to assist with interpreting the FISH results. Reported
sensitivity and specificity levels were even higher when brushing samples were
obtained from nodules rather than pan-brushing.

Douglas VanOort, the company's Chairman and CEO, commented, "This FISH test is
specifically designed to help pathologists and clinicians monitor BE patients
and make more informed treatment decisions. With our commercial launch of
this test, we become the first lab in the U.S to offer this important FISH
test on a national basis. This extensive development effort is evidence of
our commitment to offer highly innovative molecular and genetic tests to
support pathologists and clinicians, and to improve patient care."

Dr. Maher Albitar, the Company's Chief Medical Officer and Director of
Research and Development, commented, "Improving surveillance in BE patients
results in better and potentially earlier treatment for those patients who are
likely to progress to esophageal cancer. Our unique approach of performing
FISH testing on brushing samples provides a reliable and an objective means of
detecting high grade dysplasia and cancer. We believe it will enable a major
step forward in BE surveillance programs as it allows clinicians to more
easily and frequently tests their BE patients and track quantitative findings
over the monitoring period."

About NeoGenomics, Inc.

NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that
specializes in cancer genetics testing, the fastest growing segment of the
laboratory industry. The company's testing services include cytogenetics,
fluorescence in-situ hybridization (FISH), flow cytometry,
immunohistochemistry, morphology studies, anatomic pathology and molecular
genetic testing. Headquartered in Fort Myers, FL, NeoGenomics has labs in
Nashville, TN, Irvine, CA, Tampa, FL and Fort Myers, FL. NeoGenomics services
the needs of pathologists, oncologists, urologists and other clinicians, and
hospitals throughout the United States. For additional information about
NeoGenomics, visit

Forward Looking Statements

Except for historical information, all of the statements, expectations and
assumptions contained in the foregoing are forward-looking statements. These
forward looking statements involve a number of risks and uncertainties that
could cause actual future results to differ materially from those anticipated
in the forward looking statements. Actual results could differ materially
from such statements expressed or implied herein. Factors that might cause
such a difference include, among others, the company's ability to continue
gaining new customers, offer new types of tests, and otherwise implement its
business plan. As a result, this press release should be read in conjunction
with the company's periodic filings with the SEC.

SOURCE NeoGenomics, Inc.

Contact: Steven C. Jones, NeoGenomics, Inc., Director of Investor Relations,
+1-239-325-2001,; Ms. Julie Marshall, Hawk Associates,
Inc., +1-305-451-1888,
Press spacebar to pause and continue. Press esc to stop.